Regulatory role of cytokines in disseminated intravascular coagulation

Seminars in Thrombosis and Hemostasis

Volumn 27, Issue 6, 2001, Pages 639-651

  Van der Poll, T ^a   De Jonge, E ^a   Levi, M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Coagulation; Cytokines; Endotoxin; Fibrinolysis; Protein C

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; PROTEIN C; PROTEIN S; THROMBOMODULIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR;

ARTICLE; BLOOD CLOTTING; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INFLAMMATION; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SEPSIS;

ANIMALS; BLOOD COAGULATION; CYTOKINES; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; SEPSIS;

EID: 0035217872     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18868     Document Type: Article

References (129)

1. Role of cytokines in sepsis
2. Cytokines and anti-cytokines in the pathogenesis of sepsis
3. Measurement of inflammatory mediators in clinical sepsis
4. Compartimentalized cytokine production within the human lung in unilateral pneumonia
5. Perioperative pattern of peritoneal interleukin 8, tumour necrosis factorα, and granulocyte elastase release in human secondary peritonitis
6. Levels of inhibitors of tumor necrosis factor-α and interleukin 1 in urine and sera of patients with urosepsis
7. Interleukin-10 production during septicaemia
8. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: Sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10 and IL-13 concentrations
9. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo
10. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia
11. Endotoxemia in healthy subjects as a human model of inflammation
12. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees
13. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans
14. Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees
15. Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: Relation to plasma levels of interleukin-10 and interferon-γ
16. Inhibition of the release of soluble tumour necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-α antibody
17. Shock and tissue injury induced by recombinant human cachectin
18. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition
19. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production
20. Effects of recombinant human interleukin-6 in cancer patients: A phase I/II study
21. Endocrine and metabolic effects of interleukin-6 in humans
22. Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog
23. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
24. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF)
25. Interleukin 1 receptor antagonist reduces mortality from endotoxin shock
26. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia
27. Defective inflammatory response in interleukin-6-deficient mice
28. Role of interferon-γ in experimental gram-negative sepsis
29. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice
30. Interferon-γ receptor deficient mice are resistant to endotoxic shock
31. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance
32. IL-10 controls IFN-γ and TNF production during experimental endotoxemia
33. IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: Correlation with down-modulation of TNF-α, IFN-γ, and IL-12 production
34. Disseminated intravascular coagulation
35. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infections related to unfavourable prognosis
36. Comparison of the capacity of rhTNF-alpha and Escherichia coli to induce procoagulant activity by baboon mononuclear cells in vivo and in vitro
37. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody
38. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees
39. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa
40. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli
41. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
42. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock
43. Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activation without influencing the fibrinolytic and the cytokine response during human endotoxemia
44. Modulation of endothelial cell hemostatic properties by tumor necrosis factor
45. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity
46. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor
47. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes
48. IL-4 inhibits LPS-, IL-1β- and TNFα-induced expression of tissue factor in endothelial cells and monocytes
49. IL-4 and IL-13 exhibit comparable abilities to reduce pyrogen-induced expression of procoagulant activity in endothelial cells and monocytes
50. The effect of interleukin-4 on tumour necrosis factor-alpha induced expression of tissue factor and plasminogen activator inhibitor-1 in human umbilical vein endothelial cells
51. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity
52. Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogeneous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors
53. Functional activities of receptors for tumor necrosis factor-a on human vascular endothelial cells
54. Both tumor necrosis factor receptors, TNFR60 and TNFR80, are involved in signaling endothelial tissue factor expression by juxtracrine tumor necrosis factor alpha
55. Th1 and Th2 T-helper cells exert opposite effects on procoagulant activity and tissue factor production by human monocytes
56. Inhibition of IL-1 induced tissue factor (TF) synthesis and procoagulant activity (PCA) in purified human monocytes by IL-4, IL-10 and IL-13
57. Inhibition of tissue factor surface expression in human peripheral blood monocytes exposed to cytokines
58. Tissue factor induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells
59. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity
60. Leukemia inhibitory factor enhances tissue factor expression in human monocyte-derived macrophages: A gp130-mediated mechanism
61. Bacterial species-and strain-dependent induction of tissue factor in human vascular endothelial cells
62. Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide
63. Interleukin-10 and pentoxifylline inhibit C-reactive protein-induced tissue factor gene expression in peripheral human blood monocytes
64. Tissue factor expression in endothelial cell/monocyte cocultures stimulated by lipopolysaccharide and/or aggregated IgG. Mechanisms of cell: Cell communication
65. Induction of tissue factor on monocytes by adhesion to endothelial cells
66. Activation of coagulation after administration of tumor necrosis factor to normal subjects
67. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans
68. Tumor necrosis factor induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor
69. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans
70. 2 in sepsis. Studies in non-human primates following interleukin-1 administration and during lethal bacteremia
71. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans
72. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees
73. Interleukin 12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees
74. Interleukin-2 induces activation of coagulation and fibrinolysis: Resemblance to the changes seen during endotoxaemia
75. Interleukin 10 inhibits activation of coagulation and fibrinolysis during human endotoxemia
76. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia
77. New potential therapeutic modalities: APC
78. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex
79. The endothelial cell protein C receptor: Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors
80. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
81. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis
82. C4b-binding protein exacerbates the host response to Escherichia coli
83. Regulation of thrombomodulin by tumor necrosis factor-α: Comparison of transcriptional and posttranscriptional mechanism
84. Differential effect of tumor necrosis factor-α on thrombomodulin gene expression by human monocytoid (THP-1) cells versus endothelial cells
85. Regulation of thrombomodulin expression by all-trans retinoic acid and tumor necrosis factor-α: Differential responses in keratinocytes and endothelial cells
86. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor
87. Metalloproteolytic release of endothelial cell protein C receptor
88. Thrombomodulin release in baboon sepsis: Its dependence on the dose of Escherichia coli and the presence of tumor necrosis factor
89. Regulation of murine protein C gene expression in vivo: Effects of tumor necrosis factor-α, interleukin-1 and transforming growth factor-β
90. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli
91. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor
92. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-β, lipopolysaccharide, and tumor necrosis factor-α
93. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells
94. IFN-γ inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells
95. Interferon-γ modulates the fibrinolytic response in cultured human endothelial cells
96. Increased secretion of urokinase-type plasminogen activator by human lung microvascular endothelial cells
97. Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by gamma-interferon
98. Interleukin-4 stimulates expression of urokinase-type-plasminogen activator in cultured human foreskin microvascular endothelial cells
99. PAI-1 synthesis in the human hepatoma cell line HepG2 is increased by cytokines. Evidence that the liver contributes to acute phase behaviour of PAI-1
100. Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response
101. Interleukin-1 induction of type-1 plasminogen activator inhibitor (PAI-1) gene expression in the mouse hepatocyte line, AML 12
102. Urokinase and type 1 plasminogen activator inhibitor production by normal hepatocytes: Modulation by inflammatory agents
103. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects
104. Fibrinolytic response to tumor necrosis factor in healthy subjects
105. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products
106. Plasminogen activator and its inhibitor in cancer patients treated with tumor necrosis factor
107. Induction of plasminogen activator inhibitor type 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-α
108. IL-1β mediates induction of hepatic type I plasminogen activator inhibitor in response to local tissue injury
109. Coagulation of whole blood stimulates interleukin-1β gene expression
110. Thrombin and factor Xa enhance the production ofinterleukin-1
111. The proinflammatory cytokine response to coagulation and endotoxin in whole blood
112. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation
113. Thrombin-induced interleukin-8 production and its regulation by interferon-γ and prostaglandin E2 in human monocytic U937 cells
114. Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha thrombin
115. Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells
116. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells
117. Thrombin stimulates production of interleukin-8 in human endothelial cells
118. Thrombin activates nuclear factor-κB and potentiates endothelial cell activation by TNF
119. The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to transplant biology and therapy
120. Selective inhibitor effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-γ, or phorbol ester
121. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats
122. Immunobiology and therapeutic applications of protein C/protein S/thrombomodulin in human and experimental allotransplantation and xenotransplantation
123. The up-regulation of IL-6 and IL-8 in human endothelial cells by activated protein C
124. Monocyte-macrophage release of IL-1 is inhibited by type-1 plasminogen activator inhibitor
125. Endogenously produced urokinase amplifies tumor necrosis factor-α secretion by THP-1 mononuclear phagocytes
126. U937 cells can utilize plasminogen activator to regulate human interferon-γ
127. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage
128. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats
129. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes